MarketVIEW: *Campylobacter jejuni* vaccines (CAT: VAMV071)

**Product Name**: MarketVIEW: *Campylobacter jejuni* vaccines

**Description**: Vaccine commercial opportunity assessment

**Contents**: Executive presentation (.pdf) + 1 commercial forecast model(s) (.xls)

**Therapeutic Area**: Endemic/travel vaccines

**Publication date**: November 2016

**Catalogue No**: VAMV071

**Background**

*Campylobacter jejuni* is a major cause of gastroenteritis worldwide and is also associated with Guillain-Barré syndrome (GBS) and other complications. The main symptom, gastroenteritis occurs within 24–72 hours of ingestion. Infection usually manifests as acute watery or bloody diarrhoea, fever, weight loss and cramps that lasts ~6 days. *Campylobacteriosis* is the sixth most common known cause of diarrhoeal death in children aged <5 years. It is the also most common cause of bacterial gastroenteritis, responsible for 7.5 million DALYs in 2010. Campylobacter can also affect Western travellers to endemic countries.

There is considerable potential value in a vaccine against *Campylobacter* for humans and animals. In humans, the potential relates to the prevention of not just acute infection, but also the sequelae of campylobacteriosis, which could lead to a great reduction in the burden of disease. Potential target groups include children living in developing countries, travellers and the military.

This MarketVIEW product is composed of a comprehensive MS Excel-based model + Summary Presentation that forecasts the potential commercial value of *Campylobacter jejuni* vaccines across 47 endemic countries to 2035. Three scenarios (LO, BASE and HI) are included based upon successive targeting of endemic countries based upon DALYs per WHO region. A travelers forecast from major Western points of origin is also included. The report covers a detailed review of disease background and epidemiology along with current treatment, unmet needs and rationale for vaccine approach. An ideal Target Product Profile (TPP) is defined along with commercial model assumptions with pricing justification.
Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to endemic/travel vaccines and novel approaches to enteric/diarrhoeal pathogens. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of bacterial/nosocomial vaccines has also been utilised.

**PRODUCT CONTENTS:**
**Published November 2016 (CAT No: VAMV071)**

****This product is composed of one forecast model (.xls)¹ and a summary presentation (.pdf)²

Contents
Author's note
Executive summary
Key commercial model outputs
[Section] Commercial model: key outputs
Campylobacter vaccines: global forecast revenue ($m) to 2035
Campylobacter vaccines: global forecast volume (000s doses) to 2035
Campylobacter vaccines: endemic countries volume and value by scenario, region and country to 2035
Campylobacter vaccines: endemic countries volume (000s doses) by five largest countries in each WHO region
Campylobacter vaccines: endemic country market share in 2030 by region and country
Campylobacter vaccines: traveller countries volume (000s doses) and value ($m) by region of origin
Campylobacter vaccines: traveller market share and value ($000s) by country of origin
Campylobacter vaccines: traveller market share in 2030 by destination region
Campylobacter vaccines: traveller volume by origin region to destination region
[Section] Campylobacter jejuni: disease background and epidemiology
Transmission of Campylobacter
Pathophysiology of campylobacteriosis
Clinical presentation of campylobacteriosis
Complications of campylobacteriosis (gastrointestinal)
Complications of campylobacteriosis (Guillain-Barre Syndrome, GBS)
Campylobacter is an important cause of morbidity globally
Campylobacteriosis is an important foodborne illness
Incidence and prevalence of campylobacteriosis globally
Incidence, deaths and DALYs from Campylobacter per 100,000 persons
DALYs caused Campylobacter infection by WHO subregion
Risk factors for campylobacteriosis - developing regions
Risk factors for campylobacteriosis - industrialised regions
Risk factors for campylobacteriosis in travellers
Economic burden of campylobacteriosis
Treatment of campylobacteriosis
[Section] Campylobacter jejuni: capsular polysaccharide and serotyping:

¹ Model contents available upon request
² Presentation titles may apply to more than one slide
Continued……

*C. jejuni* capsular polysaccharide (CPS): a unique feature for an enteric pathogen
*C. jejuni* CPS determines the Penner serotype
Worldwide distribution of *C. jejuni* serotypes
A multiplex PCR typing system to replace Penner serotyping

[Section] Developing a *Campylobacter jejuni* vaccine: rationale and approaches
Approaches to a *Campylobacter* vaccine
Multivalency of a *Campylobacter* vaccine
*Campylobacter* vaccine: target product profile (TPP)
Rationale for vaccination against *Campylobacter jejuni*

[Section] *Campylobacter jejuni* vaccines in development: overview of current R&D
CJCV1 – CPS-conjugate vaccine (US Department of Defense)
PEB1 DNA vaccine (Shandong Medical College, China)
Other approaches being investigated

[Section] *Campylobacter jejuni* vaccines: modelling commercial potential
Modelling methodology: overview
Countries included in endemic model
Modelling assumptions: endemic countries
Modelling assumptions: endemic - launch, coverage and pricing
Destination countries included in traveller model
Modelling assumptions: traveller target populations
Travellers seeking advice (North America and ROW)
Travellers seeking advice (Europe and Scandinavia)
Modelling assumptions: travellers – risk status, introduction and pricing
Vaccine coverage rates in travellers
Bibliography
Disclaimer

About VacZine Analytics

Slide number = 67
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD $9995.00/ GBP £7870.00* (Region license)*

*Indicative company rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total
Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.
BIBLIOGRAPHY

46. Lu PJ, et al. Hepatitis A vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity, United States. Vaccine 2013;31:2348.
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009